FDA actions, PCAC votes, the bulks lists, state boards, enforcement letters — tracked continuously, verified against primary sources, and translated into what it actually means for compounding pharmacies, clinics, and telehealth operators.
Tampa, Florida
Since the July PCAC vote, most of what's circulating about where the six peptides stand is wrong. This is the verified, cited, one-page read — where each one actually sits today, and what that means in practice.
Enter your email and the Q3 brief arrives immediately, along with Peptide Regulation Watch — the ongoing record of what changed and what it means. No pitch. Unsubscribe any time.
Send me the briefDelivered via Peptide Regulation Watch. Your email is never shared or sold.
Don't take the word "verified" on faith — read the work. Every issue is dated, sourced, and checked against the primary record before it goes out.
FDA & PCAC actions, 503A/503B bulks lists, regulations.gov dockets, state board actions, warning letters.
Claims are checked against the primary source — the docket, the letter, the list itself — never against what a rep or a forum says.
Not legal commentary — the practical read: what changed, who it touches, and what's worth a closer look this month.
David Ramsingh is the founder of Ramsingh Analytics, an independent regulatory-intelligence practice based in Tampa, Florida.
The practice exists because of a gap he kept running into: the peptide space moves on rumor. After the FDA's April 2026 category actions and the July PCAC vote, operators across the industry — pharmacies, clinics, telehealth companies — were making real business decisions based on secondhand summaries that turned out to be wrong. The people with the most at stake had the least reliable information.
Ramsingh Analytics does the unglamorous part: reading the dockets, the lists, and the letters as they land, verifying what's actually true, and keeping a running record operators can check their assumptions against. The research is the practice — everything published here is the same material David works from himself.
He spends his weeks meeting the people who live these rules — pharmacists, clinic owners, prescribers — because the regulatory record only means something next to the operational reality.
Questions, corrections, or a perspective from inside the industry — all welcome.
In Tampa Bay? The coffee's on me.